Pre‐operative neoadjuvant vinblastine‐prednisolone in canine mast cell tumours: A single‐centre retrospective cohort study

Abstract

AbstractNeoadjuvant chemotherapy can be used in canine mast cell tumours (MCTs) to optimise surgical margins or to enable marginal excision in challenging locations. The objective of this study was to describe the outcome of dogs with cutaneous and subcutaneous MCTs treated with neoadjuvant vinblastine‐prednisolone (NA‐VP). Records of treatment‐naïve dogs with cutaneous/subcutaneous MCT that received NA‐VP were reviewed including signalment, indication for NA‐VP, staging results, clinical response, surgical data and histopathology reports. For dogs with post‐operative follow‐up ≥365 days, predictive factors for local recurrence (LR) were evaluated. Forty‐four dogs were included. NA‐VP was indicated to optimise surgical margins (group MARG) in 19 dogs (43.2%) and to enable surgery (group MORB) in 25 dogs (56.8%). Complete and partial response were documented in 40.9% of dogs and 30 dogs (68.2%) underwent surgery. The indication for NA‐VP was significantly associated with undergoing surgery (p < .001) on multivariable analysis. Twelve (48%) and 18 dogs (94.7%) underwent surgery in the group MORB and MARG, respectively. Five dogs (16.7%) experienced wound dehiscence. Complete excision was achieved in 14 dogs (46.7%). In dogs undergoing surgery with ≥365 days of follow‐up, LR was documented in five cases (20.8%). None of the factors analysed including mitotic count, completeness of excision and response to NA‐VP were associated with LR; notably, LR occurred in 3/11 (27.2%) completely excised MCTs. In a pre‐operative setting, NA‐VP appears safe and could be beneficial in selected cases. Prognostic factors such as clinical response, mitotic count and completeness of excision should be interpreted with caution following NA‐VP.